IMIDomics
@IMIDomics
Followers
102
Following
35
Media
2
Statuses
50
The IMID drug discovery company. Committed to improving the lives of patients with immune-mediated inflammatory diseases.
Barcelona and San Francisco CA
Joined December 2019
What's the future of #autoimmunedisease treatment? Our partnership with @FormationBio aims to answer that question! Check out our latest video featuring Fred Craves discussing the collaboration & its potential impact on #autoimmunedisease treatment #drugdiscovery.
@IMIDomics discovered the initial science, and now.@formationbio is taking it forward to clinical development. Today we announced our license of IMIDomics' first-in-class, Phase-1 ready anti-CD226 antibody targeting Ulcerative Colitis. Go behind the scenes with both teams here.
0
4
8
Exciting news! We have partnered with @FormationBio to advance our first-in-class anti-CD226 monoclonal antibody program for #autoimmunediseases. This collaboration marks a key step in our mission to bring innovative treatments to patients currently underserved by existing IMID.
0
1
5
Thrilled to be recognized in @UCB_news’ 2024 Annual Report! Our collaboration is driving innovation in IMID research, developing targeted therapies for immune-mediated inflammatory diseases. #Biotech #IMID #Collaboration #UCB #PrecisionMedicine.
0
0
1
We are thrilled to announce that respected Matthias Evers, Ph. D., will join the IMIDomics Board of Directors effective October 1, 2024. Dr. Evers' significant expertise and insights will be critical as we advance our mission of delivering breakthrough medicines for IMIDs.
0
0
0
We are honored and excited to announce a strategic equity investment from @UCB_News Together, we look forward to advancing novel solutions that address the unmet needs of patients suffering from #IMIDs. Read more here:
ucb.com
UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases | UCB
Pleased to announce a strategic investment in IMIDomics.🎉 Their innovative approach in developing novel medicines aligns with our mission to improve patient lives. #UCB #IMIDomics #Innovation.
0
0
5
RT @ucb_news: Pleased to announce a strategic investment in IMIDomics.🎉 Their innovative approach in developing novel medicines aligns with….
0
2
0
“Today, we announced the expansion of our strategic collaboration with @bmsnews to accelerate research and development aimed at understanding and uncovering mechanisms driving Sjögren's disease and atopic dermatitis.”.
businesswire.com
IMIDomics, a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), announced today that it is expa...
0
0
1
Thrilled to announce Dr. Eric Perakslis as our new Senior VP & CTO, bringing stellar expertise in pharma R&D. Welcoming Dr. Ramon Felciano as a strategic advisor in biomedical AI and data science. Exciting times ahead shaping the future of IMIDomics!.
businesswire.com
IMIDomics, a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), proudly announces the addition ...
0
1
1
We are excited to announce a license and collaboration agreement with @UniBarcelona (UB) to advance treatments of #IMIDs, developing new therapeutic approaches for two new drug targets IMB-1003 and IMB-1004.
businesswire.com
IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced a strategi...
0
2
5
Congratulations to Dr. Sara Marsal on receiving the Trifermed Award for Social Impact in Healthcare!.Dr. Marsal's remarkable dedication to the field of rheumatology and her outstanding contributions to the understanding and treatment of IMIDs.
0
2
5
Today, we announced a strategic agreement with @WuXiBiologics to accelerate the development and manufacturing of IMIDomics IMB1001, a highly promising humanized antibody targeting CD226, a breakthrough target for treating #IMIDs. Read more:
businesswire.com
IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced that it ha...
0
1
4
We are excited to announce our multi-program collaboration with @TwistBioscience to conduct antibody discovery activities against targets for patients with #IMIDs. Read more:
businesswire.com
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pla...
0
0
3
IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases.
businesswire.com
IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced an exclusi...
0
1
5
We’re thrilled to announce the creation of our Immunology Advisory Board. The luminaries will support us refine our Precision Discovery Engine, and moving forward with identifying and pursuing targets for potential new treatments#IMIDs.
businesswire.com
IMIDomics, Inc., a biotechnology company focused on the discovery and development of new medicines for the treatment of patients with immune-mediated inflamm...
0
2
3
RT @biocat_es: 📰 Las #biotech del @PCB_UB captan 39 M€, las más destacadas: .👉 @_inBrain 14,3 M€.👉 @IMIDomics 16,5 M€. ✅ El vivero de la @U….
0
3
0
@IMIDomics is proud to have contributed to the early identification of #abatacept as a candidate immune modulator to reduce mortality in severe #COVID19
NIH ACTIV-1 clinical trial on immunomodulators for severe #COVID19 is out! In line with our prediction, #abatacept reduces the risk of death .
0
0
2
Proud to receive this recognition from the CataloniaBio & HealthTech. It reflects our continuous commitment to IMID patients.
0
1
4
RT @VHIR_: . @IMIDomics, spin-off de #VallHebron centrada en el descubrimiento y desarrollo de nuevas dianas y medicamentos para el tratami….
0
1
0
We are thrilled to announce that @Evotec has made a strategic investment in IMIDomics that reflects our shared goal of leveraging data to discover and develop meaningful treatments to improve the health and quality of life of IMID patients.
businesswire.com
IMIDomics, Inc., a privately held global biotechnology company focused on the discovery and development of new targets and medicines for the treatment of pat...
0
4
12
We’re thrilled to announce the creation of our Scientific Advisory Board and Business Advisory Board. The esteemed members will support us as we continue our precision discovery efforts to identify new therapies for #IMIDs. More Information:
businesswire.com
IMIDomics Inc., a global biotechnology company focused on the discovery and development of new medicines for the treatment of patients with immune-mediated i...
0
2
3